Clinical Endoscopy

  • 제44권2호
  • /
  • Pages.101-108
  • /
  • 2011
  • /
  • 2234-2400(pISSN)
  • /
  • 2234-2443(eISSN)
대한소화기내시경학회 (The Korean Society of Gastrointestinal Endoscopy)
권호 표지
DOI QR코드

DOI QR Code

Low Grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Clinicopathological Factors Associated with Helicobacter pylori Eradication and Tumor Regression

  • Choi, Yoon-Jin (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lee, Dong-Ho (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Kim, Ji-Yeon (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kwon, Ji-Eun (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Jae-Yeon (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Jo, Hyun-Jin (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Shin, Cheol-Min (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Kim, Hyun-Young (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Park, Young-Soo (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Kim, Na-Young (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Jung, Hyun-Chae (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Song, In-Sung (Department of Internal Medicine, Seoul National University College of Medicine)
  • 발행 : 2011.12.30
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Eradication of Helicobacter pylori is widely accepted as initial therapy for low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, approximately 20% of patients with this disease are not responsive to H. pylori eradication therapy. The aim of this study was to assess remission and relapse rates of low-grade gastric MALT lymphoma after H. pylori eradication and identify the clinical factors that affect remission. Methods: Thirty-nine patients diagnosed with gastric MALT lymphoma (May 2003 to May 2010) were retrospectively analyzed. Results: Of the 39 patients, 30 (77%) had a H. pylori infection. There were 35/39 (90%) patients with stage I. Among stage I, 25 patients with the infection underwent eradication therapy and 22/25 (88%) achieved remission. The total regression rate with eradication only in stage I was 24/28 (86%). The median time to remission was 98 days (range, 22 to 397 days). Age, tumor location, invasion depth, H. pylori burden, and severity of mononuclear leukocyte and neutrophil infiltration were not related to remission. However, patients with less neutrophil infiltration were more likely to achieve a successful first H. pylori eradication (p=0.049). Conclusions: The results show that the rate of low-grade gastric MALT lymphoma regression (86%) with H. pylori eradication alone was higher than that in Western studies (77.8%) and that neutrophil infiltration was inversely related to success of the first H. pylori eradication procedure.

키워드

참고문헌

  1. Brooks JJ, Enterline HT. Primary gastric lymphomas. A clinicopathologic study of 58 cases with long-term follow-up and literature review. Cancer 1983;51:701-711. https://doi.org/10.1002/1097-0142(19830215)51:4<701::AID-CNCR2820510425>3.0.CO;2-D
  2. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252-260. https://doi.org/10.1002/1097-0142(197201)29:1<252::AID-CNCR2820290138>3.0.CO;2-#
  3. Lim FE, Hartman AS, Tan EG, Cady B, Meissner WA. Factors in the prognosis of gastric lymphoma. Cancer 1977;39:1715-1720. https://doi.org/10.1002/1097-0142(197704)39:4<1715::AID-CNCR2820390449>3.0.CO;2-M
  4. Sandler RS. Has primary gastric lymphoma become more common? J Clin Gastroenterol 1984;6:101-107. https://doi.org/10.1097/00004836-198404000-00001
  5. Severson RK, Davis S. Increasing incidence of primary gastric lymphoma. Cancer 1990;66:1283-1287. https://doi.org/10.1002/1097-0142(19900915)66:6<1283::AID-CNCR2820660631>3.0.CO;2-4
  6. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983; 52:1410-1416. https://doi.org/10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3
  7. Enno A, O'Rourke JL, Howlett CR, Jack A, Dixon MF, Lee A. MALToma-like lesions in the murine gastric mucosa after long-term infection with Helicobacter felis. A mouse model of Helicobacter pylori-induced gastric lymphoma. Am J Pathol 1995;147:217-222.
  8. Isaacson PG, Spencer J. Gastric lymphoma and Helicobacter pylori. Important Adv Oncol 1996:111-121.
  9. Nakamura S, Aoyagi K, Furuse M, et al. B-cell monoclonality precedes the development of gastric MALT lymphoma in Helicobacter pylori-associated chronic gastritis. Am J Pathol 1998;152:1271-1279.
  10. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267-1271. https://doi.org/10.1056/NEJM199405053301803
  11. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175-1176. https://doi.org/10.1016/0140-6736(91)92035-Z
  12. Pinotti G, Zucca E, Roggero E, et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma 1997;26:527-537. https://doi.org/10.3109/10428199709050889
  13. Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW. Textbook of Gastroenterology. 5th ed. Oxford: Wiley-Blackwell; 2008. p. 1044-1046.
  14. Eck M, Schmausser B, Haas R, Greiner A, Czub S, Müller-Hermelink HK. MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology 1997;112:1482-1486. https://doi.org/10.1016/S0016-5085(97)70028-3
  15. Wotherspoon AC. Gastric lymphoma of mucosa-associated lymphoid tissue and Helicobacter pylori. Annu Rev Med 1998;49:289-299. https://doi.org/10.1146/annurev.med.49.1.289
  16. Zullo A, Hassan C, Andriani A, et al. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol 2009;104:1932-1937. https://doi.org/10.1038/ajg.2009.314
  17. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004;53:34-37. https://doi.org/10.1136/gut.53.1.34
  18. Suzuki H, Saito Y, Hibi T. Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma: updated review of clinical outcomes and the molecular pathogenesis. Gut Liver 2009;3:81-87. https://doi.org/10.5009/gnl.2009.3.2.81
  19. Wündisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005;23:8018-8024. https://doi.org/10.1200/JCO.2005.02.3903
  20. Lee SK, Lee YC, Chung JB, et al. Endoscopic findings and results of long-term follow-up of low grade gastric MALT lymphoma. Korean J Gastrointest Endosc 2003;26:192-198.
  21. Park KJ, Kim DH, Kim SH, et al. A clinical study of the therapeutic outcome of low-grade gastric MALT lymphoma. Chonnam Med J 2006; 42:94-100.
  22. Hong SS, Jung HY, Choi KD, et al. A prospective analysis of low-grade gastric malt lymphoma after Helicobacter pylori eradication. Helicobacter 2006;11:569-573. https://doi.org/10.1111/j.1523-5378.2006.00460.x
  23. Fischbach W, Dragosics B, Kolve-Goebeler ME, et al. Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology 2000;119:1191-1202. https://doi.org/10.1053/gast.2000.19579
  24. Steinbach G, Ford R, Glober G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 1999;131:88-95. https://doi.org/10.7326/0003-4819-131-2-199907200-00003
  25. Stolte M, Bayerdorffer E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut 2002;50(Suppl):iii19-iii24. https://doi.org/10.1136/gut.50.suppl_3.iii19
  26. Chung JB. Gastroenterology. 1st ed. Seoul: Koonja; 2009. p. 322-323.
  27. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001;357:39-40. https://doi.org/10.1016/S0140-6736(00)03571-6
  28. Nakamura T, Inagaki H, Seto M, Nakamura S. Gastric low-grade B-cell MALT lymphoma: treatment, response, and genetic alteration. J Gastroenterol 2003;38:921-929. https://doi.org/10.1007/s00535-003-1234-4
  29. Sleisenger MH, Fordtran JS, Feldman ML, Scharschmidt B. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 6th ed. Philadelphia: Saunders; 1998. p. 450-452.
  30. Kim SJ, Yang S, Min BH, et al. Helicobacter pylori eradication for stage IE1 gastric mucosa-associated lymphoid tissue lymphoma: predictive factors of complete remission. Korean J Gastroenterol 2010;55:94-99. https://doi.org/10.4166/kjg.2010.55.2.94
  31. Gisbert JP, Olivares D, Jimenez I, Pajares JM. Long-term follow-up of 13C-urea breath test results after Helicobacter pylori eradication: frequency and significance of borderline delta13CO2 values. Aliment Pharmacol Ther 2006;23:275-280. https://doi.org/10.1111/j.1365-2036.2006.02741.x

피인용 문헌

  1. A Polypoid Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach Treated with Endoscopic Polypectomy vol.46, pp.6, 2011, https://doi.org/10.5946/ce.2013.46.6.647
  2. Antisecretory medication is associated with decreased Helicobacter pylori detection in gastric marginal zone lymphoma vol.19, pp.6, 2011, https://doi.org/10.1016/j.anndiagpath.2015.10.001
  3. Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori -Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma vol.10, pp.5, 2016, https://doi.org/10.5009/gnl15510
  4. Bone marrow involvement is not associated with the clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma vol.51, pp.8, 2011, https://doi.org/10.3109/00365521.2016.1151929
  5. Clinical Efficacy of Radiotherapy inHelicobacter pyloriNegative or Unresponsive to Eradication Therapy Primary Gastric Mucosa-Associated Lymphoid Tissue Lymphoma vol.73, pp.1, 2019, https://doi.org/10.4166/kjg.2019.73.1.19
  6. Endoscopic features aiding the diagnosis of gastric mucosa-associated lymphoid tissue lymphoma vol.36, pp.2, 2011, https://doi.org/10.12701/yujm.2019.00136
  7. Clinical efficacy of the modified Helicobacter pylori eradication therapy for Helicobacter pylori -negative gastric mucosa-associated lymphoid tissue lymphoma: a meta analysis vol.133, pp.11, 2020, https://doi.org/10.1097/cm9.0000000000000813
  8. Efficacy of eradication therapy in Helicobacter pylori‐negative gastric mucosa‐associated lymphoid tissue lymphoma: A meta‐analysis vol.26, pp.2, 2021, https://doi.org/10.1111/hel.12774